Duoperone

Duoperone

SCHEMBL2109141

O=C(c1ccc(F)cc1)C1CCN(CCCN2c3ccccc3Sc3ccc(C(F)(F)F)cc32)CC1

nearest known ligand 0.70

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FPR2 P25090 12/20 0.70
LMNA P02545 6/20 0.65
MAPT P10636 6/20 0.65
CYP3A4 P08684 4/20 0.65
MAPK1 P28482 4/20 0.65
USP2 O75604 4/20 0.65
TP53 P04637 3/20 0.65
DRD2 P14416 3/20 0.65
DRD1 P21728 3/20 0.65
HRH1 P35367 3/20 0.65
DRD3 P35462 3/20 0.65
ABCB11 O95342 2/20 0.65
CYP1A2 P05177 2/20 0.65
ABCB1 P08183 2/20 0.65
HTR1A P08908 2/20 0.65
ADRA2A P08913 2/20 0.65
ADORA3 P0DMS8 2/20 0.65
CYP2D6 P10635 2/20 0.65
CHRM1 P11229 2/20 0.65
ADRA2B P18089 2/20 0.65

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Duoperone SCHEMBL29694381 1.00 FPR2 (0.70) FPR2LMNAMAPTCYP3A4MAPK1
Duoperone SCHEMBL121486 0.95 FPR2 (0.64) FPR2LMNAMAPTCYP3A4MAPK1
Duoperone SCHEMBL121485 0.95 FPR2 (0.64) FPR2LMNAMAPTCYP3A4MAPK1
SCHEMBL11746346 0.90 HTR2A (0.61) LMNACYP3A4MAPK1USP2DRD2
SCHEMBL11750190 0.88 DRD2 (0.70) FPR2LMNACYP3A4MAPK1USP2
SCHEMBL11743885 0.88 DRD2 (0.73) FPR2LMNAMAPTCYP3A4MAPK1
Hydrochloric Acid SCHEMBL11747251 0.87 DRD2 (0.57) FPR2LMNACYP3A4MAPK1USP2
SCHEMBL9678662 0.86 FPR2 (0.61) FPR2LMNAMAPTCYP3A4MAPK1
Hydrochloric Acid SCHEMBL11749117 0.86 DRD2 (0.71) FPR2LMNAMAPTCYP3A4MAPK1
SCHEMBL9676172 0.85 DRD2 (0.55) FPR2LMNAMAPTCYP3A4MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9016221-B2 Surface topographies for non-toxic bioadhesion control UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) 2015-04-28 US claimed
US-20100226943-A1 SURFACE TOPOGRAPHIES FOR NON-TOXIC BIOADHESION CONTROL UNIVERSITY OF FLORIDA (US) 2010-09-09 US claimed
CN-101330905-A Freeze-drying process and products obtained thereby SCIDOSE LLC (US) 2008-12-24 CN claimed
EP-1954244-A1 LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY Scidose, Llc (US) 2008-08-13 EP claimed
WO-2007061529-A1 LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY SCIDOSE LLC. (US) 2007-05-31 WO claimed
US-20070116729-A1 Lyophilization process and products obtained thereby SCIDOSE LLC 2007-05-24 US claimed
US-4021552-A TRANQUILIZERS A. H. ROBINS COMPANY, INCORPORATED (US) 1977-05-03 US claimed
US-20220047505-A1 Controlled Absorption Water-Soluble Pharmaceutically Active Organic Compound Formulation for Once-Daily Administration STI PHARMA, LLC (US) 2022-02-17 US disclosed
US-11191719-B2 Controlled absorption water-soluble pharmaceutically active organic compound formulation for once-daily administration STI PHARMA, LLC (US) 2021-12-07 US disclosed
US-10463611-B2 Controlled absorption water-soluble pharmaceutically active organic compound formulation for once-daily administration STI PHARMA, LLC (US) 2019-11-05 US disclosed
US-9494572-B2 Method and compositions for treating cancer and related methods ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) 2016-11-15 US disclosed
US-9134297-B2 Method and compositions for treating cancer and related methods ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) 2015-09-15 US disclosed
US-20150224101-A1 Method and Compositions for Treating Cancer and Related Methods ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI 2015-08-13 US disclosed
US-20040141922-A1 Diagnostic/therapeutic agents NYCOMED IMAGING AS 2004-07-22 US disclosed
US-6680047-B2 FOR USE IN ULTRASOUND IMAGING, CONTRAST AGENTS AMERSHAM HEALTH AS (NO) 2004-01-20 US disclosed
US-20020102215-A1 Diagnostic/therapeutic agents NYCOMED IMAGING AS 2002-08-01 US disclosed
US-20020102217-A1 Diagnostic/therapeutic agents NYCOMED IMAGING AS 2002-08-01 US disclosed
US-6331289-B1 ULTRASOUND CONTRAST AGENTS, SUSPENSION IN AQUEOUS CARRIER LIQUID OF A REPORTER COMPRISING GAS-CONTAINING OR GAS-GENERATING MATERIAL, AGENT CAPABLE OF FORMING AT LEAST TWO TYPES OF BINDING PAIRS WITH TARGET; REPORTER BEING CONJUGATED NYCOMED IMAGING AS (NO) 2001-12-18 US disclosed
US-6264917-B1 MIXTURE OF GAS FILLED MICROBUBBLES AND RELEASING AGENT NYCOMED IMAGING AS (NO) 2001-07-24 US disclosed
US-6261537-B1 TARGETS AND ULTRASOUND DIAGNOSIS OF ACTIVE MATERIALS, AQUEOUS CARRIER LIQUIDS, CARRIERS AND FILM FORMING SURFACTANT PHOSPHATIDES NYCOMED IMAGING AS (NO) 2001-07-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040141922-A1 Diagnostic/therapeutic agents BID, FUS, FABP1 FPR2 805/4885LMNA 1461/4885MAPT 1721/4885
US-20020102215-A1 Diagnostic/therapeutic agents BID, FUS, FABP1 FPR2 1052/4885LMNA 1552/4885MAPT 2239/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.